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We would like to thank Yang and colleagues for their attempt
to determine the possibility of delayed hepatic recovery with N-
acetylcysteine (NAC) administration in acetaminophen-induced
hepatotoxicity [1]. We are concerned, however, about the
possible consequences that may arise from their conclusions.
Owing to the wide availability of acetaminophen, intentional
and unintentional overdoses are one of the leading causes of
liver failure in the world [2]. NAC is currently a highly effective
and safe antidote to treat acute acetaminophen overdose,
and is most efficacious when administered within 8 hours of
ingestion [3]. Furthermore, one landmark study showed that
even in patients who presented with delayed acetaminophen-
induced fulminant hepatic failure, intravenous NAC adminis-
tration improved survival versus control individuals (48% vs.
20%) [4]. Another study found that the infusion of acetyl-
cysteine in patients with acetaminophen-induced liver failure
resulted in an increase in mean oxygen delivery and in an in-
creased mean arterial pressure [5].
It is difficult to believe that the mouse model of Yang and
colleagues has any correlation to humans, since the already
established human data are so overwhelmingly positive. The
amount of acetaminophen administered in their study caused
hepatotoxicity but did not induce death, and therefore is not
applicable to real-life situations where people may ingest
potentially fatal doses of acetaminophen.
It is not clear to us why the authors came to explore this study
topic. The conclusions drawn from their article are potentially
dangerous and should be viewed with caution and
scepticism.
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NAC = N-acetylcysteine.
Authors’ response
Runkuan Yang, Keita Miki, Xin He, Meaghan E Killeen and Mitchell P Fink
We would like to point out the following factors.
Firstly, NAC treatment was effective at the 24 hours timepoint
in our study.
Also, the main treatment duration in the paper of Keays and
colleagues was 20 hours [4]. Even though a low dose of
NAC infusion was continued after the main treatment, this
therapy was discontinued when patients recovered from
encephalopathy. It is not clear for how long this NAC
treatment was given in surviving patients and in nonsurviving
patients.
Finally, Harrison and colleagues’ patients were treated with
NAC for 4 hours and 15 minutes [5] – the treatment was
therefore not prolonged.
Acetaminophen is frequently used by patients with chronic
pain. Acetaminophen hepatotoxicity in these patients is
treated with NAC for longer than the standard 20 hours in
some hospitals. At present, NAC is also used to treat
nonacetaminophen-induced hepatotoxicity [6,7]. The median
duration of NAC administration in children with
nonacetaminophen-induced acute liver injury is 5 days (range,
1 to 77 days) [7]. There are, however, only limited data avail-
able on the efficacy and safety of NAC. It is therefore
important to know the safety and efficacy of prolonged NAC
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